Skip to content

A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)

A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003077
Enrollment
Unknown
Registered
2020-03-02
Start date
2020-02-27
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus; 2. Confirmed as a novel coronavirus pneumonia common and severe patients, meets the diagnostic criteria of the "novel coronavirus pneumonia diagnosis and treatment plan (trial implementation of the sixth edition)" 3. aged 18 to 65 years; 4. Learn about the significance of the study before the trial also the possible inconveniences and potential risk.

Exclusion criteria

Exclusion criteria: 1. Patients with mild and critical novel coronavirus pneumonia; 2. Acute respiratory disease caused by non- novel coronavirus pneumonia; 3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency disease acquired immunodeficiency syndrome congenital respiratory malformation congenital heart disease pulmonary dysplasia and other diseases; 4. Patients with obvious abnormal heart, liver and kidney disease or serious other system diseases such as digestive system urogenital system blood system hemorrhagic disease central nervous system psychiatric diseases in acute stage, and endocrine and metabolic diseases; 5. People who are known to be allergic to the ingredients in the research drug, or patients with allergies; 6. Women who are breastfeeding, pregnant, or have a positive urine pregnancy test; 7. Patients who are participating in other clinical trials or patients who have participated in other drug clinical trials within 1 month; 8. Researchers find the patient inappropriate to be involved in the trial.

Design outcomes

Primary

MeasureTime frame
Effective rate of TCM symptoms;fever clearance time;

Secondary

MeasureTime frame
lung CT scan;TCM sympton score;Oxygen saturation;blood routine test;duration of hospital stay;severe and critical conversion rates;clearance time of COVID-19;body tempture;

Countries

China

Contacts

Public ContactXiuming Song

Shuguang Hospital Affiliated to Shanghai University of T.C.M.

Xiumingsong@sina.com+86 13817525012

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026